Advances in the understanding of the biology of malignant lymphoma has facilitated the development of numerous molecularly targeted therapies. The incorporation of these precision therapeutics has produced more effective and often less-toxic treatment regimens leading to a significant improvement of treatment outcomes for individuals with lymphoid malignancies.In relapsed diseases, molecularly targeted therapeutic approaches have demonstrated superior outcomes compared to conventional chemotherapy, leading to a growing number of patients being treated entirely chemotherapy-free. This review outlines the current landscape of targeted therapies for both B-cell (B-NHL) and T-cell non-Hodgkin lymphomas (T-NHL) and provides an overview of targeted agents currently approved for the treatment of malignant lymphoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2160-5353 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.
Leuk Lymphoma
January 2025
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Flavonoids of Diels et Gilg Against Acute Hepatic Injury by Blocking PI3K/AKT Signaling Pathway.
Mediators Inflamm
January 2025
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
This study aims to investigate the mechanism of Diels et Gilg flavonoids (THF) on acute hepatic injury (AHI). First, high-performance liquid chromatography (HPLC) fingerprints were established to obtain the main chemical components of THF. According to the network pharmacology databases, collect active targets of AHI and potential targets.
View Article and Find Full Text PDFPostoperative stage 0 Hodgkin lymphoma. Is surgery alone a curative option?
Hemasphere
January 2025
Department of Hematology CHU de Rennes Rennes France.
Integrating Network Pharmacology and In Silico Analysis to Explore the Bioactive Compounds Against Gastric Cancer Treatment.
Cureus
December 2024
Community Medicine, Siksha 'O' Anusandhan Deemed to be University Institute of Medical Sciences and SUM Hospital, Bhubaneswar, IND.
Gastric cancer (GC) has become a major challenge in oncology research, primarily due to its detection at advanced stages. In this study, we identified and validated the pharmacological mechanisms involved in treating gastric cancer using an integrated approach combining network pharmacology, molecular docking, and a dynamic approach. Gastric cancer-related genes were obtained from DisGeNET, Genecard, and Malacard databases, while potential targets of bioactive compounds were predicted using SwissTargetPrediction.
View Article and Find Full Text PDFSuccessful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report.
Cureus
December 2024
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JPN.
A 69-year-old Japanese male with follicular lymphoma and renal pelvic carcinoma presented with fever and cough, testing positive for SARS-CoV-2 via PCR. Chest CT revealed ground-glass opacities. Initially, his symptoms improved with a 10-day course of remdesivir (RDV), but they recurred.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!